-
1.发明申请Melanoma-associated MHC class I associated oligopeptides and the uses thereof 审中-公开黑素瘤相关的MHC I类相关寡肽及其用途公开(公告)号：US20090104186A1
公开(公告)日：2009-04-23
申请号：US11991339
申请日：2006-08-31
申请人： Daniela Eberts , Martina Fatho , Volker Lennerz , Chris Schmidt , Pierre Van Der Bruggen , Catherine Wolfel , Thomas Wolfel
发明人： Daniela Eberts , Martina Fatho , Volker Lennerz , Chris Schmidt , Pierre Van Der Bruggen , Catherine Wolfel , Thomas Wolfel
CPC分类号： A61K39/0011 , A61K38/1774 , A61K2039/57 , A61K2039/572 , A61K2039/585 , C07K14/4748 , C07K16/3053
摘要： The present invention relates to certain melanoma-associated oligopeptides that are recognized by CD8-positive cytotoxic T-lymphocytes (CTLs) as peptide antigen and which elicit a CTL-induced lysis and/or apoptosis of tumor cells. The present invention also relates to the use of these melanoma-associated oligopeptides in cancer therapy.
摘要翻译： 本发明涉及由CD8阳性细胞毒性T淋巴细胞（CTLs）识别为肽抗原并引起CTL诱导的肿瘤细胞裂解和/或凋亡的某些黑素瘤相关寡肽。 本发明还涉及这些黑素瘤相关寡肽在癌症治疗中的用途。
-
2.发明申请Detection of Individual T-Cell Reaction Patterns Against Tumor-Associated Antigens (TAA) in Tumor Patients as a Basis for the Individual Therapeutic Vaccination of Patients 有权检测肿瘤患者肿瘤相关抗原（TAA）的个体T细胞反应模式作为个体治疗性接种疫苗的依据公开(公告)号：US20100035267A1
公开(公告)日：2010-02-11
申请号：US12519315
申请日：2007-11-28
申请人： Martina Fatho , Emmanuelle Wesarg , Volker Lennerz , Pierre Van Der Bruggen , Thomas Wölfel , Serena Debo
发明人： Martina Fatho , Emmanuelle Wesarg , Volker Lennerz , Pierre Van Der Bruggen , Thomas Wölfel , Serena Debo
CPC分类号： C07K14/4748 , G01N33/505 , G01N2333/70539
摘要： The present invention relates to a method for identifying the preferential target antigens of antitumoural T-cells of a tumour patient, comprising: a) providing T-cells from the blood of at least one tumour patient, b) providing dendritic cell (DCs) and/or B-lymphocytes (BLCs) that are autologous for said tumour patient, wherein said DCs and BLCs were transfected beforehand with a selection of mRNAs encoding for T-cell-immunogenic tumour-associated antigens (TAA), and express these, c) contacting said T-cells with the DCs and/or BLCs, d) identifying of those T-cells that recognize antigens of the DCs and/or BLCs, and e) identifying of the preferential target antigens of antitumoural T-cells of the at least one tumour patient on the basis of the T-cells that recognize antigens of the DCs and/or BLCs. The method can furthermore comprise the expansion of the T-cells that recognize the antigens of the DCs and/or BLCs. The present invention furthermore relates to a method for producing an individualized tumour vaccine or individualized tumour therapeutic, as well as corresponding methods for treating a tumourous disease using the individualised tumour vaccine or individualised tumour therapeutic.
摘要翻译： 本发明涉及用于鉴定肿瘤患者的抗肿瘤T细胞的优先靶抗原的方法，包括：a）从至少一个肿瘤患者的血液提供T细胞，b）提供树突状细胞（DC）和 或所述肿瘤患者自体的B淋巴细胞（BLC），其中所述DC和BLC预先用编码T细胞免疫原性肿瘤相关抗原（TAA）的mRNA的选择进行转染，并表达这些，c） 使所述T细胞与DC和/或BLC接触，d）识别识别DC和/或BLC的抗原的那些T细胞，以及e）至少鉴定所述T细胞的抗肿瘤T细胞的优先靶抗原 一个肿瘤患者基于识别DC和/或BLC的抗原的T细胞。 该方法还可以包括识别DC和/或BLC的抗原的T细胞的扩增。 本发明还涉及一种用于产生个体化肿瘤疫苗或个体化肿瘤治疗剂的方法，以及使用个体化肿瘤疫苗或个体化肿瘤治疗剂治疗肿瘤疾病的相应方法。
-
3.发明授权Detection of individual T-cell reaction patterns against tumor-associated antigens (TAA) in tumor patients as a basis for the individual therapeutic vaccination of patients 有权在肿瘤患者中检测针对肿瘤相关抗原（TAA）的单个T细胞反应模式作为患者个体治疗性接种的基础公开(公告)号：US08349558B2
公开(公告)日：2013-01-08
申请号：US12519315
申请日：2007-11-28
申请人： Martina Fatho , Emmanuelle Wesarg , Volker Lennerz , Pierre Van Der Bruggen , Thomas Wölfel , Serena Debo
发明人： Martina Fatho , Emmanuelle Wesarg , Volker Lennerz , Pierre Van Der Bruggen , Thomas Wölfel , Serena Debo
CPC分类号： C07K14/4748 , G01N33/505 , G01N2333/70539
摘要： The present invention relates to a method for identifying the preferential target antigens of antitumoural T-cells of a tumour patient, comprising: a) providing T-cells from the blood of at least one tumour patient, b) providing dendritic cell (DCs) and/or B-lymphocytes (BLCs) that are autologous for said tumour patient, wherein said DCs and BLCs were transfected beforehand with a selection of mRNAs encoding for T-cell-immunogenic tumour-associated antigens (TAA), and express these, c) contacting said T-cells with the DCs and/or BLCs, d) identifying of those T-cells that recognize antigens of the DCs and/or BLCs, and e) identifying of the preferential target antigens of antitumoural T-cells of the at least one tumour patient on the basis of the T-cells that recognize antigens of the DCs and/or BLCs. The method can furthermore comprise the expansion of the T-cells that recognize the antigens of the DCs and/or BLCs. The present invention furthermore relates to a method for producing an individualized tumour vaccine or individualized tumour therapeutic, as well as corresponding methods for treating a tumourous disease using the individualised tumour vaccine or individualised tumour therapeutic.
摘要翻译： 本发明涉及用于鉴定肿瘤患者的抗肿瘤T细胞的优先靶抗原的方法，包括：a）从至少一个肿瘤患者的血液提供T细胞，b）提供树突状细胞（DC）和 或所述肿瘤患者自体的B淋巴细胞（BLC），其中所述DC和BLC预先用编码T细胞免疫原性肿瘤相关抗原（TAA）的mRNA的选择进行转染，并表达这些，c） 使所述T细胞与DC和/或BLC接触，d）识别识别DC和/或BLC的抗原的那些T细胞，以及e）至少鉴定所述T细胞的抗肿瘤T细胞的优先靶抗原 一个肿瘤患者基于识别DC和/或BLC的抗原的T细胞。 该方法还可以包括识别DC和/或BLC的抗原的T细胞的扩增。 本发明还涉及一种用于产生个体化肿瘤疫苗或个体化肿瘤治疗剂的方法，以及使用个体化肿瘤疫苗或个体化肿瘤治疗剂治疗肿瘤疾病的相应方法。
-
-
搜索结果
3 条记录 (耗时 0.024 秒)
